How much revenue does Dezhan Healthcare make?

Dezhan Healthcare reported 396.81 million CNY in revenue for fiscal year 2025, down 14.9% from 466.49 million CNY in fiscal year 2024. In Q1 2026 revenue was 88.62 million CNY.

What is Dezhan Healthcare's largest business segment?

Pharmaceutical Industry, with 394.03 million CNY or 99% of segment revenue in fiscal year 2025. Next: Peptides (under 1%) and Other (under 1%).

Where does Dezhan Healthcare make most of its revenue?

China: 100% of revenue by region in fiscal year 2025, followed by Overseas (under 1%).

What companies are similar to Dezhan Healthcare?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Changzhou Qianhong Biopharma Co.,ltd (002550.SZ), Beijing Foyou Pharma Co.,ltd (601089.SS), Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ), Cisen Pharmaceutical Co., Ltd. (603367.SS).

Dezhan Healthcare Company Limited (000813.SZ) Stock

About Dezhan Healthcare Company Limited

Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People's Republic of China. The company offers atorvastatin calcium tablets, amlodipine-atorvastatin calcium tablets, warfarin sodium tablets, trimetazidine hydrochloride tablets, amiodarone hydrochloride tablets, as well as other drugs, including famc...

At a glance

Dezhan Healthcare reported revenue of 396.81 million CNY for fiscal year 2025, down 14.9% from fiscal year 2024, and net income of -345.42 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 88.62 million CNY, down 0.7% from a year before. Its largest business segment, Pharmaceutical Industry, brought in 99% of segment revenue in fiscal year 2025; China was the largest region with 100%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.